PDF(Pubmed)
Abstract：
UNASSIGNED: Administering adjuvant therapy following liver resection is crucial for patients with hepatocellular carcinoma (HCC) exhibiting high-risk recurrence factors. Immune checkpoint inhibitors (ICIs) are effective against unresectable HCC; however, their effectiveness and safety for this specific patient group remain uncertain.
UNASSIGNED: We conducted an extensive literature search across four scholarly databases to identify relevant studies. Our primary endpoints were overall survival (OS), recurrence-free survival (RFS), and adverse events (AEs). OS and RFS were quantified using hazard ratios (HRs), whereas the 1-, 2-, and 3-year OS and RFS rates were expressed as risk ratios (RRs). Additionally, the incidence of AEs was calculated.
UNASSIGNED: Our meta-analysis included 11 studies (N = 3,219 patients), comprising two randomized controlled trials (RCTs) and nine retrospective studies. Among these, eight studies reported HRs for OS, showing a statistically significant improvement in OS among patients receiving adjuvant ICIs (HR, 0.60; 95% confidence interval [CI], 0.45-0.80; p < 0.0001). All included studies reported HRs for RFS, indicating a favorable impact of adjuvant ICIs (HR, 0.62; 95% CI, 0.52-0.73; p < 0.0001). Moreover, aggregated data demonstrated improved 1- and 2-year OS and RFS rates with adjuvant ICIs. The incidence rate of AEs of any grade was 0.70 (95% CI, 0.49-0.91), with grade 3 or above AEs occurring at a rate of 0.12 (95% CI, 0.05-0.20).
UNASSIGNED: Adjuvant ICI therapy can enhance both OS and RFS rates in patients with HCC exhibiting high-risk recurrence factors, with manageable AEs.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/#recordDetails PROSPERO, identifier CRD42023488250.
UNASSIGNED: We conducted an extensive literature search across four scholarly databases to identify relevant studies. Our primary endpoints were overall survival (OS), recurrence-free survival (RFS), and adverse events (AEs). OS and RFS were quantified using hazard ratios (HRs), whereas the 1-, 2-, and 3-year OS and RFS rates were expressed as risk ratios (RRs). Additionally, the incidence of AEs was calculated.
UNASSIGNED: Our meta-analysis included 11 studies (N = 3,219 patients), comprising two randomized controlled trials (RCTs) and nine retrospective studies. Among these, eight studies reported HRs for OS, showing a statistically significant improvement in OS among patients receiving adjuvant ICIs (HR, 0.60; 95% confidence interval [CI], 0.45-0.80; p < 0.0001). All included studies reported HRs for RFS, indicating a favorable impact of adjuvant ICIs (HR, 0.62; 95% CI, 0.52-0.73; p < 0.0001). Moreover, aggregated data demonstrated improved 1- and 2-year OS and RFS rates with adjuvant ICIs. The incidence rate of AEs of any grade was 0.70 (95% CI, 0.49-0.91), with grade 3 or above AEs occurring at a rate of 0.12 (95% CI, 0.05-0.20).
UNASSIGNED: Adjuvant ICI therapy can enhance both OS and RFS rates in patients with HCC exhibiting high-risk recurrence factors, with manageable AEs.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/#recordDetails PROSPERO, identifier CRD42023488250.
摘要：
■肝切除术后的辅助治疗对于表现出高风险复发因素的肝细胞癌（HCC）患者至关重要。免疫检查点抑制剂（ICIs）对不可切除的HCC有效；然而，其对该特定患者组的有效性和安全性仍不确定.
■我们在四个学术数据库中进行了广泛的文献检索，以确定相关研究。我们的主要终点是总生存期（OS），无复发生存率（RFS），和不良事件（AE）。OS和RFS使用风险比(HR)进行量化，而1-，2-,3年OS和RFS率表示为风险比(RRs)。此外,计算AE的发生率.
■我们的荟萃分析包括11项研究（N=3,219例患者），包括两项随机对照试验（RCT）和9项回顾性研究。其中,八项研究报告了OS的HR，在接受辅助ICIs的患者中，OS有统计学上的显着改善(HR，0.60；95%置信区间[CI]，0.45-0.80；p<0.0001）。所有纳入的研究都报告了RFS的HR，表明佐剂ICIs(HR，0.62；95%CI，0.52-0.73；p<0.0001)。此外，汇总数据表明，使用辅助ICIs可提高1年和2年OS和RFS率。任何级别的不良事件发生率为0.70（95％CI，0.49-0.91），3级或以上不良事件发生率为0.12（95%CI，0.05-0.20）。
■辅助ICI治疗可以提高表现出高风险复发因素的HCC患者的OS和RFS率。具有可管理的AE。
■https://www.crd.约克。AC.uk/prospro/#recordDetailsPROSPERO,标识符CRD42023488250。
■我们在四个学术数据库中进行了广泛的文献检索，以确定相关研究。我们的主要终点是总生存期（OS），无复发生存率（RFS），和不良事件（AE）。OS和RFS使用风险比(HR)进行量化，而1-，2-,3年OS和RFS率表示为风险比(RRs)。此外,计算AE的发生率.
■我们的荟萃分析包括11项研究（N=3,219例患者），包括两项随机对照试验（RCT）和9项回顾性研究。其中,八项研究报告了OS的HR，在接受辅助ICIs的患者中，OS有统计学上的显着改善(HR，0.60；95%置信区间[CI]，0.45-0.80；p<0.0001）。所有纳入的研究都报告了RFS的HR，表明佐剂ICIs(HR，0.62；95%CI，0.52-0.73；p<0.0001)。此外，汇总数据表明，使用辅助ICIs可提高1年和2年OS和RFS率。任何级别的不良事件发生率为0.70（95％CI，0.49-0.91），3级或以上不良事件发生率为0.12（95%CI，0.05-0.20）。
■辅助ICI治疗可以提高表现出高风险复发因素的HCC患者的OS和RFS率。具有可管理的AE。
■https://www.crd.约克。AC.uk/prospro/#recordDetailsPROSPERO,标识符CRD42023488250。
